The global companion animal specialty drugs market is poised for steady growth over the next decade, according to a new report by Future Market Insights. The market, currently valued at USD 37,624.67 Million in 2022, is expected to reach an impressive USD 56,828.56 Million by 2032, with a moderate-paced CAGR of 4.21% during the forecast period.
Key Growth Drivers:
The expansion of the companion animal specialty drugs market is being fueled by several significant factors, including:
- Rising Pet Adoption and Urbanization: With increasing urbanization and the shift toward nuclear families, there is a surge in pet ownership. This trend is driving the demand for specialized care and medications for companion animals.
- Focus on Animal Health and Growing Demand for Pet Insurance: In developed countries, there is a growing emphasis on the well-being of pets, supported by the rising adoption of pet insurance. This is facilitating better access to advanced medical treatments, further boosting the market for companion animal specialty drugs.
- Increasing Incidence of Animal Diseases: The rising number of health conditions affecting companion animals, such as kidney concerns, heartworm, and Lyme disease, is generating substantial demand for effective drugs and treatments.
- Rise in Zoonotic and Food-borne Diseases: The growing incidence of zoonotic diseases, along with food-borne illnesses, is prompting a higher demand for specialty medications that help mitigate these risks in companion animals.
- Rising Per Capita Income: Increased disposable income, particularly in urban areas, is enabling pet owners to invest in advanced treatments and diagnostics for their animals. This includes vaccines and disease mitigation options, further contributing to the market’s growth.
Market Constraints
Despite these encouraging growth indicators, there are challenges that may hinder the market’s full potential:
- Risk of Side Effects: Concerns about potential side effects, such as mild vomiting after the administration of certain drugs, could limit adoption if proper guidelines are not followed.
- High Cost of Specialty Drugs: The high costs associated with companion animal specialty drugs remain a significant barrier, particularly for middle-class pet owners in low-income regions. Lack of affordability and awareness about these treatments in certain areas can limit market penetration.
- Lack of Awareness: In several regions, especially in low-income countries, awareness of advanced treatments for companion animals is still low. This lack of education among pet owners is expected to impede the growth of the market in these areas.
Growing Market Interest: Explore Comprehensive Insights and Trends with Our Detailed Report!
Future Outlook
Despite these challenges, the companion animal specialty drugs market is expected to witness steady growth due to increasing focus on animal health, better insurance coverage, and growing awareness of the importance of proper diagnosis and treatment. As urbanization continues to rise and more individuals adopt pets, the demand for advanced healthcare solutions for companion animals is projected to remain strong over the coming decade.
“Surge in the introduction of new veterinary medicines, rise in the number of pet owners, and growing awareness of animal health are furling the global growth of the companion animal specialty drugs market over the forecast period,” says an FMI analyst.
Key Takeaways:
- Surging number of animal healthcare centers and NGOs will strengthen the market prospects.
- The companion animal specialty drugs market in the U.S. will account for 88% of the North American market share.
- Brazil’s companion animal specialty drugs market will be valued at USD 426 Million in 2022.
- The companion animal specialty drugs market in Germany will expand at a CAGR of 2.4%.
- Online veterinary pharmacies will grow at a CAGR of 6.8%.
- The parasiticide drug segment accounted for a market share of 32.2% in
- By product type, the vaccines segment will reach a value of USD 2.89 Billion in 2022.
- By route of administration, the oral segment will account for a value of USD 2.86 Billion in 2022.
Competitive Landscape:
Key Industry Players Transform and Elevate the Companion Animal Specialty Drugs Market
The global companion animal specialty drugs market is experiencing rapid growth, driven by the presence of leading industry players and emerging start-ups. Companies are actively pursuing innovative strategies to develop new companion animal drugs that minimize side effects. These advancements are expected to fuel the market’s continued expansion.
Industry leaders are focusing on launching new products and adopting inorganic growth strategies to stay competitive. Strategic partnerships with other companies are enhancing product portfolios, allowing them to deliver high-quality solutions and expand their customer base.
Recent Developments:
- In February 2021, Vetoquinol acquired the Canadian rights to the Profender product line from Elanco Animal Health. This acquisition is set to boost Vetoquinol’s revenue and unlock business opportunities in new markets.
- In August 2020, Elanco Animal Health completed its acquisition of Bayer Animal Health in a transaction valued at USD 6.89 billion. This move strengthened Elanco’s position in the long-term animal health industry.
Some of the key companies proliferating in the market are:
- Merck Animal Health (Merck & Co., Inc.)
- Boehringer Ingelheim International GmbH.
- Elanco Animal Health Incorporated
- Virbac S.A.
- Biogenesis Bago SA
- Piramal Group
- Zoetis
- NEOGEN Corporation.
- Vetoquinol S.A.
- Ceva Santé Animale
Key Segments in the Companion Animal Specialty Drugs Market:
By Product:
- Antibiotics
- Anti-Inflammatory Drugs
- Parasiticides
- Heartworm
- Behavioral Products
- Nutritional Products
- Anti-Obesity Drugs
- Skin Care Products
- Vaccines
By Distribution Channel:
- Modern Trade
- Online Distribution
- Neighborhood Stores
- Other Retail Format
By Region:
- North America
- Latin America
- Asia Pacific
- MEA
- Europe
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
